(APEI) American Public Education - Overview
Sector: Consumer DefensiveIndustry: Education & Training Services | Exchange NASDAQ (USA) | Currency USD | Market Cap: 1.076m | Total Return 150.4% in 12m
Stock: Education, Degrees, Certificates, Nursing, Career
Total Rating 76
Risk 84
Buy Signal 1.34
| Risk 5d forecast | |
|---|---|
| Volatility | 61.3% |
| Relative Tail Risk | -16.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.19 |
| Alpha | 136.82 |
| Character TTM | |
|---|---|
| Beta | 1.130 |
| Beta Downside | 2.898 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.97% |
| CAGR/Max DD | 3.15 |
EPS (Earnings per Share)
Revenue
Description: APEI American Public Education March 03, 2026
American Public Education, Inc. (APEI) is a provider of online and campus-based postsecondary education, operating through the American Public University System, Rasmussen University, and Hondros College of Nursing. The company manages a portfolio of 182 degree and 136 certificate programs, with a strategic focus on nursing, healthcare, and specialized fields relevant to the federal government and military sectors.
The business model relies heavily on serving non-traditional students and the military-connected demographic, where tuition is often funded through federal programs such as the Department of Defense Tuition Assistance and the GI Bill. This positioning within the Education Services sub-industry makes the company sensitive to federal regulatory changes regarding Title IV funding and gainful employment mandates.
For a deeper look into the companys valuation metrics, you may want to explore the data on ValueRay. APEI remains headquartered in West Virginia and continues to expand its footprint in pre-licensure nursing and health sciences to address national labor shortages in the healthcare sector.
Headlines to watch out for
- Enrollment trends in online degree programs impact revenue
- Regulatory changes in higher education affect operations
- Competition for adult learners influences market share
- Healthcare education demand drives nursing program growth
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 31.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.61 > 1.0 |
| NWC/Revenue: 28.48% < 20% (prev 29.05%; Δ -0.57% < -1%) |
| CFO/TA 0.11 > 3% & CFO 62.0m > Net Income 31.6m |
| Net Debt (-13.5m) to EBITDA (64.2m): -0.21 < 3 |
| Current Ratio: 3.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.7m) vs 12m ago 1.60% < -2% |
| Gross Margin: 53.59% > 18% (prev 0.53%; Δ 5.31k% > 0.5%) |
| Asset Turnover: 116.5% > 50% (prev 109.6%; Δ 6.99% > 0%) |
| Interest Coverage Ratio: 11.36 > 6 (EBITDA TTM 64.2m / Interest Expense TTM 4.23m) |
Altman Z'' 2.64
| A: 0.34 (Total Current Assets 259.8m - Total Current Liabilities 75.0m) / Total Assets 543.4m |
| B: -0.03 (Retained Earnings -16.5m / Total Assets 543.4m) |
| C: 0.09 (EBIT TTM 48.1m / Avg Total Assets 556.8m) |
| D: -0.07 (Book Value of Equity -16.3m / Total Liabilities 248.7m) |
| Altman-Z'' Score: 2.64 = A |
Beneish M -2.98
| DSRI: 1.00 (Receivables 65.7m/63.4m, Revenue 648.9m/624.6m) |
| GMI: 0.98 (GM 53.59% / 52.65%) |
| AQI: 1.15 (AQ_t 0.29 / AQ_t-1 0.25) |
| SGI: 1.04 (Revenue 648.9m / 624.6m) |
| TATA: -0.06 (NI 31.6m - CFO 62.0m) / TA 543.4m) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of APEI shares?
As of March 27, 2026, the stock is trading at USD 57.42 with a total of 285,873 shares traded.
Over the past week, the price has changed by +5.32%, over one month by +25.84%, over three months by +53.24% and over the past year by +150.41%.
Over the past week, the price has changed by +5.32%, over one month by +25.84%, over three months by +53.24% and over the past year by +150.41%.
Is APEI a buy, sell or hold?
American Public Education has received a consensus analysts rating of 4.40.
Therefore, it is recommended to buy APEI.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the APEI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56.2 | -2.2% |
| Analysts Target Price | 56.2 | -2.2% |
APEI Fundamental Data Overview March 27, 2026
P/E Trailing = 41.8143
P/E Forward = 22.9358
P/S = 1.6583
P/B = 3.3621
P/EG = 1.5296
Revenue TTM = 648.9m USD
EBIT TTM = 48.1m USD
EBITDA TTM = 64.2m USD
Long Term Debt = 94.7m USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last quarter)
Debt = 163.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.06b USD (1.08b + Debt 163.0m - CCE 176.5m)
Interest Coverage Ratio = 11.36 (Ebit TTM 48.1m / Interest Expense TTM 4.23m)
EV/FCF = 23.05x (Enterprise Value 1.06b / FCF TTM 46.1m)
FCF Yield = 4.34% (FCF TTM 46.1m / Enterprise Value 1.06b)
FCF Margin = 7.10% (FCF TTM 46.1m / Revenue TTM 648.9m)
Net Margin = 4.86% (Net Income TTM 31.6m / Revenue TTM 648.9m)
Gross Margin = 53.59% ((Revenue TTM 648.9m - Cost of Revenue TTM 301.1m) / Revenue TTM)
Gross Margin QoQ = 53.85% (prev 54.23%)
Tobins Q-Ratio = 1.96 (Enterprise Value 1.06b / Total Assets 543.4m)
Interest Expense / Debt = 0.72% (Interest Expense 1.17m / Debt 163.0m)
Taxrate = 29.17% (5.19m / 17.8m)
NOPAT = 34.0m (EBIT 48.1m * (1 - 29.17%))
Current Ratio = 3.46 (Total Current Assets 259.8m / Total Current Liabilities 75.0m)
Debt / Equity = 0.55 (Debt 163.0m / totalStockholderEquity, last quarter 294.8m)
Debt / EBITDA = -0.21 (Net Debt -13.5m / EBITDA 64.2m)
Debt / FCF = -0.29 (Net Debt -13.5m / FCF TTM 46.1m)
Total Stockholder Equity = 289.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.67% (Net Income 31.6m / Total Assets 543.4m)
RoE = 10.92% (Net Income TTM 31.6m / Total Stockholder Equity 289.1m)
RoCE = 12.52% (EBIT 48.1m / Capital Employed (Equity 289.1m + L.T.Debt 94.7m))
RoIC = 9.12% (NOPAT 34.0m / Invested Capital 373.4m)
WACC = 8.72% (E(1.08b)/V(1.24b) * Re(9.96%) + D(163.0m)/V(1.24b) * Rd(0.72%) * (1-Tc(0.29)))
Discount Rate = 9.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.11%
[DCF] Terminal Value 79.29% ; FCFF base≈38.8m ; Y1≈47.8m ; Y5≈81.6m
[DCF] Fair Price = 67.18 (EV 1.22b - Net Debt -13.5m = Equity 1.23b / Shares 18.4m; r=8.72% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 20.62 | EPS CAGR: 35.78% | SUE: 1.90 | # QB: 2
Revenue Correlation: 75.85 | Revenue CAGR: 0.61% | SUE: 4.0 | # QB: 5
EPS next Quarter (2026-06-30): EPS=0.50 | Chg7d=+0.025 | Chg30d=+0.025 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=2.86 | Chg7d=+0.130 | Chg30d=+0.130 | Revisions Net=+2 | Growth EPS=+30.4% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=3.73 | Chg7d=+0.375 | Chg30d=+0.375 | Revisions Net=+2 | Growth EPS=+30.6% | Growth Revenue=+6.5%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.6% (Discount Rate 10.0% - Earnings Yield 2.4%)
[Growth] Growth Spread = -4.5% (Analyst 3.1% - Implied 7.6%)
P/E Forward = 22.9358
P/S = 1.6583
P/B = 3.3621
P/EG = 1.5296
Revenue TTM = 648.9m USD
EBIT TTM = 48.1m USD
EBITDA TTM = 64.2m USD
Long Term Debt = 94.7m USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last quarter)
Debt = 163.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.06b USD (1.08b + Debt 163.0m - CCE 176.5m)
Interest Coverage Ratio = 11.36 (Ebit TTM 48.1m / Interest Expense TTM 4.23m)
EV/FCF = 23.05x (Enterprise Value 1.06b / FCF TTM 46.1m)
FCF Yield = 4.34% (FCF TTM 46.1m / Enterprise Value 1.06b)
FCF Margin = 7.10% (FCF TTM 46.1m / Revenue TTM 648.9m)
Net Margin = 4.86% (Net Income TTM 31.6m / Revenue TTM 648.9m)
Gross Margin = 53.59% ((Revenue TTM 648.9m - Cost of Revenue TTM 301.1m) / Revenue TTM)
Gross Margin QoQ = 53.85% (prev 54.23%)
Tobins Q-Ratio = 1.96 (Enterprise Value 1.06b / Total Assets 543.4m)
Interest Expense / Debt = 0.72% (Interest Expense 1.17m / Debt 163.0m)
Taxrate = 29.17% (5.19m / 17.8m)
NOPAT = 34.0m (EBIT 48.1m * (1 - 29.17%))
Current Ratio = 3.46 (Total Current Assets 259.8m / Total Current Liabilities 75.0m)
Debt / Equity = 0.55 (Debt 163.0m / totalStockholderEquity, last quarter 294.8m)
Debt / EBITDA = -0.21 (Net Debt -13.5m / EBITDA 64.2m)
Debt / FCF = -0.29 (Net Debt -13.5m / FCF TTM 46.1m)
Total Stockholder Equity = 289.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.67% (Net Income 31.6m / Total Assets 543.4m)
RoE = 10.92% (Net Income TTM 31.6m / Total Stockholder Equity 289.1m)
RoCE = 12.52% (EBIT 48.1m / Capital Employed (Equity 289.1m + L.T.Debt 94.7m))
RoIC = 9.12% (NOPAT 34.0m / Invested Capital 373.4m)
WACC = 8.72% (E(1.08b)/V(1.24b) * Re(9.96%) + D(163.0m)/V(1.24b) * Rd(0.72%) * (1-Tc(0.29)))
Discount Rate = 9.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.11%
[DCF] Terminal Value 79.29% ; FCFF base≈38.8m ; Y1≈47.8m ; Y5≈81.6m
[DCF] Fair Price = 67.18 (EV 1.22b - Net Debt -13.5m = Equity 1.23b / Shares 18.4m; r=8.72% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 20.62 | EPS CAGR: 35.78% | SUE: 1.90 | # QB: 2
Revenue Correlation: 75.85 | Revenue CAGR: 0.61% | SUE: 4.0 | # QB: 5
EPS next Quarter (2026-06-30): EPS=0.50 | Chg7d=+0.025 | Chg30d=+0.025 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=2.86 | Chg7d=+0.130 | Chg30d=+0.130 | Revisions Net=+2 | Growth EPS=+30.4% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=3.73 | Chg7d=+0.375 | Chg30d=+0.375 | Revisions Net=+2 | Growth EPS=+30.6% | Growth Revenue=+6.5%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.6% (Discount Rate 10.0% - Earnings Yield 2.4%)
[Growth] Growth Spread = -4.5% (Analyst 3.1% - Implied 7.6%)